Verdicts genuinely change. Free email alert the moment PHPSX's does — no target price to set, unlike "Alert" above.
Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
PHARMACEUTICALS ULTRASECTOR PROFUND · ProFunds
74 holdings
This fund holds short positions, so exposure is counted gross — long and short both count as exposure rather than netting off, and the weights below therefore sum to 102% of net assets rather than 100%. Shares of the portfolio are shown as shares of that gross exposure.
NON-COMPLIANT At least 25.87% of portfolio weight is in non-compliant holdings — already over the 5% threshold, so the verdict is settled whatever the unmatched 58% turns out to be. Matching more holdings can only raise this share, never lower it.
74 holdings, 42 matched (43% of weight). Portfolio as of 2026-07-31, filed 2026-09-23. Source: SEC Form N-PORT.
7.62% of this portfolio’s income is non-permissible — weighted across holdings, computed over 38% of portfolio weight (36 of 74 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
Portfolio shares are withheld: coverage is below the floor needed to state one. The holdings themselves are below, because the names are evidence you can check.
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| N/A | UNSCREENED | 8.20% | no in-house ratios for this holding |
| N/A | UNSCREENED | 6.31% | no in-house ratios for this holding |
| N/A | UNSCREENED | 5.05% | no in-house ratios for this holding |
| N/A | UNSCREENED | 5.05% | no in-house ratios for this holding |
| N/A | UNSCREENED | 3.95% | no in-house ratios for this holding |
| CRINETICS PHARMACEUTICALS INC | UNSCREENED | 2.60% | no in-house ratios for this holding |
| MBX BIOSCIENCES INC | UNSCREENED | 2.28% | no in-house ratios for this holding |
| ATAI ATAIBECKLEY INC | NON_COMPLIANT | 2.03% | AAOIFI0.9% Usmani9.4% Dow Jones Islamic2.0% S&P Shariah2.5% MSCI Islamic9.4% MSCI Islamic M-Series2.5% FTSE Shariah8.7% |
| DEFINIUM THERAPEUTICS INC | UNSCREENED | 2.00% | no in-house ratios for this holding |
| AMYLYX PHARMACEUTICALS INC | UNSCREENED | 1.62% | no in-house ratios for this holding |
| ENLIVEN THERAPEUTICS INC | UNSCREENED | 1.59% | no in-house ratios for this holding |
| CORT CORCEPT THERAPEUTICS INC | COMPLIANT | 1.57% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ALUMIS INC | UNSCREENED | 1.51% | no in-house ratios for this holding |
| N/A | UNSCREENED | 1.49% | no in-house ratios for this holding |
| NUVB NUVATION BIO INC | NON_COMPLIANT | 1.48% | AAOIFI10.5% Usmani33.9% Dow Jones Islamic18.7% S&P Shariah23.6% MSCI Islamic33.9% MSCI Islamic M-Series23.6% FTSE Shariah33.4% |
| TREVI THERAPEUTICS INC | UNSCREENED | 1.46% | no in-house ratios for this holding |
| LQDA LIQUIDIA CORP | COMPLIANT | 1.38% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| NKTR NEKTAR THERAPEUTICS | NON_COMPLIANT | 1.33% | AAOIFI3.1% Usmani7.2% Dow Jones Islamic8.2% S&P Shariah11.3% MSCI Islamic7.2% MSCI Islamic M-Series11.3% FTSE Shariah0.0% |
| AMNEAL PHARMACEUTICALS INC | UNSCREENED | 1.28% | no in-house ratios for this holding |
| BMY BRISTOL-MYERS SQUIBB COMPANY | NON_COMPLIANT | 1.26% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| EDGEWISE THERAPEUTICS INC | UNSCREENED | 1.25% | no in-house ratios for this holding |
| OMEROS CORP | UNSCREENED | 1.24% | no in-house ratios for this holding |
| LGND LIGAND PHARMACEUTICALS INC | COMPLIANT | 1.24% | AAOIFI19.7% Usmani51.8% Dow Jones Islamic34.1% S&P Shariah42.6% MSCI Islamic51.8% MSCI Islamic M-Series42.6% FTSE Shariah51.5% |
| ELAN ELANCO ANIMAL HEALTH INC | NON_COMPLIANT | 1.23% | AAOIFI31.2% Usmani27.5% Dow Jones Islamic41.7% S&P Shariah45.2% MSCI Islamic27.5% MSCI Islamic M-Series45.2% FTSE Shariah27.5% |
| VERADERMICS INC | UNSCREENED | 1.21% | no in-house ratios for this holding |
| PCRX PACIRA BIOSCIENCES INC | NON_COMPLIANT | 1.21% | AAOIFI39.2% Usmani33.1% Dow Jones Islamic41.2% S&P Shariah37.5% MSCI Islamic33.1% MSCI Islamic M-Series37.5% FTSE Shariah29.2% |
| VTRS VIATRIS INC | NON_COMPLIANT | 1.19% | AAOIFI65.8% Usmani38.9% Dow Jones Islamic100.2% S&P Shariah105.1% MSCI Islamic38.9% MSCI Islamic M-Series105.1% FTSE Shariah38.1% |
| JAZZ JAZZ PHARMACEUTICALS PLC | COMPLIANT | 1.18% | AAOIFI27.4% Usmani39.7% Dow Jones Islamic46.1% S&P Shariah49.7% MSCI Islamic39.7% MSCI Islamic M-Series49.7% FTSE Shariah39.3% |
| ETON ETON PHARMACEUTICALS INC | COMPLIANT | 1.17% | AAOIFI1.7% Usmani25.2% Dow Jones Islamic5.4% S&P Shariah7.4% MSCI Islamic25.2% MSCI Islamic M-Series7.4% FTSE Shariah24.1% |
| MAZE MAZE THERAPEUTICS INC | COMPLIANT | 1.17% | AAOIFI4.2% Usmani11.4% Dow Jones Islamicfail S&P Shariahfail MSCI Islamic11.4% MSCI Islamic M-Seriesfail FTSE Shariah7.3% |
| MRK MERCK & COMPANY INC | COMPLIANT | 1.17% | AAOIFI14.7% Usmani41.5% Dow Jones Islamic21.8% S&P Shariah20.9% MSCI Islamic41.5% MSCI Islamic M-Series20.9% FTSE Shariah41.5% |
| HROW HARROW INC | COMPLIANT | 1.16% | AAOIFI21.7% Usmani74.0% Dow Jones Islamic22.2% S&P Shariah29.2% MSCI Islamic74.0% MSCI Islamic M-Series29.2% FTSE Shariah72.0% |
| JNJ JOHNSON & JOHNSON | COMPLIANT | 1.15% | AAOIFI7.6% Usmani24.4% Dow Jones Islamic10.9% S&P Shariah11.7% MSCI Islamic24.4% MSCI Islamic M-Series11.7% FTSE Shariah24.4% |
| RPRX ROYALTY PHARMA PLC | NON_COMPLIANT | 1.15% | AAOIFI24.4% Usmani45.2% Dow Jones Islamic60.3% S&P Shariah67.3% MSCI Islamic45.2% MSCI Islamic M-Series67.3% FTSE Shariah45.2% |
| INDV INDIVIOR PHARMACEUTICALS INC | COMPLIANT | 1.12% | AAOIFI12.3% Usmani41.3% Dow Jones Islamic17.8% S&P Shariah18.8% MSCI Islamic41.3% MSCI Islamic M-Series18.8% FTSE Shariah39.5% |
| PRESTIGE CONSUMER HEALTHCARE INC | UNSCREENED | 1.09% | no in-house ratios for this holding |
| COLL COLLEGIUM PHARMACEUTICAL INC | NON_COMPLIANT | 1.09% | AAOIFI31.8% Usmani11.4% Dow Jones Islamic21.9% S&P Shariah22.5% MSCI Islamic11.4% MSCI Islamic M-Series22.5% FTSE Shariah11.2% |
| LLY ELI LILLY & COMPANY | COMPLIANT | 1.08% | AAOIFI5.2% Usmani38.6% Dow Jones Islamic6.4% S&P Shariah6.9% MSCI Islamic38.6% MSCI Islamic M-Series6.9% FTSE Shariah38.6% |
| OGN ORGANON & COMPANY | NON_COMPLIANT | 1.08% | AAOIFI236.4% Usmani64.9% Dow Jones Islamic282.4% S&P Shariah250.1% MSCI Islamic64.9% MSCI Islamic M-Series250.1% FTSE Shariah64.9% |
| EYPT EYEPOINT INC | NON_COMPLIANT | 1.06% | AAOIFIfail Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| HARMONY BIOSCIENCES HOLDINGS INC | UNSCREENED | 1.06% | no in-house ratios for this holding |
| SUPN SUPERNUS PHARMACEUTICALS INC | COMPLIANT | 1.06% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| PFE PFIZER INC | NON_COMPLIANT | 1.05% | AAOIFI39.8% Usmani31.4% Dow Jones Islamic46.1% S&P Shariah45.9% MSCI Islamic31.4% MSCI Islamic M-Series45.9% FTSE Shariah31.4% |
| WVE WAVE LIFE SCIENCES LTD | NON_COMPLIANT | 1.04% | AAOIFI3.9% Usmani7.8% Dow Jones Islamic2.9% S&P Shariah3.6% MSCI Islamic7.8% MSCI Islamic M-Series3.6% FTSE Shariah0.0% |
| PAHC PHIBRO ANIMAL HEALTH CORP | NON_COMPLIANT | 1.04% | AAOIFI43.6% Usmani45.1% Dow Jones Islamic51.7% S&P Shariah64.2% MSCI Islamic45.1% MSCI Islamic M-Series64.2% FTSE Shariah41.3% |
| ANIP ANI PHARMACEUTICALS INC | NON_COMPLIANT | 1.04% | AAOIFI18.2% Usmani20.2% Dow Jones Islamic16.9% S&P Shariah17.9% MSCI Islamic20.2% MSCI Islamic M-Series17.9% FTSE Shariah20.2% |
| TARS TARSUS PHARMACEUTICALS INC | COMPLIANT | 1.03% | AAOIFI2.3% Usmani14.5% Dow Jones Islamic3.8% S&P Shariah4.7% MSCI Islamic14.5% MSCI Islamic M-Series4.7% FTSE Shariah11.9% |
| ZTS ZOETIS INC | NON_COMPLIANT | 1.02% | AAOIFI29.0% Usmani61.3% Dow Jones Islamic15.4% S&P Shariah14.0% MSCI Islamic61.3% MSCI Islamic M-Series14.0% FTSE Shariah60.0% |
| OCUL OCULAR THERAPEUTIX INC | NON_COMPLIANT | 1.00% | AAOIFI0.3% Usmani1.0% Dow Jones Islamic0.4% S&P Shariah0.5% MSCI Islamic1.0% MSCI Islamic M-Series0.5% FTSE Shariah0.0% |
| XERS XERIS BIOPHARMA HOLDINGS INC | COMPLIANT | 1.00% | AAOIFI19.9% Usmani70.3% Dow Jones Islamic30.4% S&P Shariah39.2% MSCI Islamic70.3% MSCI Islamic M-Series39.2% FTSE Shariah61.3% |
| RAPPORT THERAPEUTICS INC | UNSCREENED | 0.99% | no in-house ratios for this holding |
| INVA INNOVIVA INC | NON_COMPLIANT | 0.98% | AAOIFI17.5% Usmani15.8% Dow Jones Islamic19.8% S&P Shariah21.9% MSCI Islamic15.8% MSCI Islamic M-Series21.9% FTSE Shariah15.2% |
| PRGO PERRIGO COMPANY PLC | NON_COMPLIANT | 0.97% | AAOIFI167.1% Usmani45.6% Dow Jones Islamic136.7% S&P Shariah120.3% MSCI Islamic45.5% MSCI Islamic M-Series120.3% FTSE Shariah43.3% |
| AXSM AXSOME THERAPEUTICS INC | COMPLIANT | 0.95% | AAOIFI1.9% Usmani29.5% Dow Jones Islamic2.9% S&P Shariah3.5% MSCI Islamic27.6% MSCI Islamic M-Series3.5% FTSE Shariah24.7% |
| AMPHASTAR PHARMACEUTICALS INC | UNSCREENED | 0.87% | no in-house ratios for this holding |
| ARVINAS INC | UNSCREENED | 0.85% | no in-house ratios for this holding |
| ALTO NEUROSCIENCE INC | UNSCREENED | 0.84% | no in-house ratios for this holding |
| SEPN SEPTERNA INC | NON_COMPLIANT | 0.71% | AAOIFI1.3% Usmani4.0% Dow Jones Islamic2.4% S&P Shariahfail MSCI Islamic4.0% MSCI Islamic M-Seriesfail FTSE Shariah0.0% |
| LB PHARMACEUTICALS INC | UNSCREENED | 0.69% | no in-house ratios for this holding |
| CORMEDIX INC | UNSCREENED | 0.68% | no in-house ratios for this holding |
| THERAVANCE BIOPHARMA INC | UNSCREENED | 0.67% | no in-house ratios for this holding |
| ACRS ACLARIS THERAPEUTICS INC | NON_COMPLIANT | 0.62% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| PHAT PHATHOM PHARMACEUTICALS INC | NON_COMPLIANT | 0.60% | AAOIFI55.2% Usmani123.6% Dow Jones Islamic53.0% S&P Shariah57.8% MSCI Islamic123.6% MSCI Islamic M-Series57.8% FTSE Shariah122.8% |
| N/A | UNSCREENED | 0.58% | no in-house ratios for this holding |
| ZEVRA THERAPEUTICS INC | UNSCREENED | 0.58% | no in-house ratios for this holding |
| RLMD RELMADA THERAPEUTICS INC | NON_COMPLIANT | 0.57% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| AQST AQUESTIVE THERAPEUTICS INC | COMPLIANT | 0.48% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| FULCRUM THERAPEUTICS INC | UNSCREENED | 0.47% | no in-house ratios for this holding |
| LXRX LEXICON PHARMACEUTICALS INC | NON_COMPLIANT | 0.42% | AAOIFI5.9% Usmani23.7% Dow Jones Islamic11.4% S&P Shariah12.0% MSCI Islamic23.7% MSCI Islamic M-Series12.0% FTSE Shariah20.6% |
| BIOA BIOAGE LABS INC | NON_COMPLIANT | 0.39% | AAOIFI0.6% Usmani0.7% Dow Jones Islamic0.6% S&P Shariah— MSCI Islamic0.7% MSCI Islamic M-Series— FTSE Shariah0.0% |
| EOLS EVOLUS INC | NON_COMPLIANT | 0.31% | AAOIFI33.8% Usmani66.4% Dow Jones Islamic29.3% S&P Shariah26.8% MSCI Islamic66.4% MSCI Islamic M-Series26.8% FTSE Shariah63.2% |
| N/A | UNSCREENED | 0.24% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.03% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
The published standards disagree about this fund by 10 points of portfolio weight — 15.7% of it passes AAOIFI, 5.7% passes MSCI Islamic. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 15.7% ratios fail on 22.2% 63.6% not rated under AAOIFI
ratios pass on 6.7% ratios fail on 29.3% 65.5% not rated under Usmani
ratios pass on 14.3% ratios fail on 21.3% 65.9% not rated under Dow Jones Islamic
ratios pass on 13.8% ratios fail on 21.5% 66.3% not rated under S&P Shariah
ratios pass on 5.7% ratios fail on 29.3% 66.5% not rated under MSCI Islamic
ratios pass on 13.3% ratios fail on 21.9% 66.3% not rated under MSCI Islamic M-Series
ratios pass on 7.9% ratios fail on 28.1% 65.5% not rated under FTSE Shariah
42 of 74 listed holdings carry our own per-methodology verdicts (44% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 36 (38% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| ATAI ATAIBECKLEY INC | 2.03% |
| NUVB NUVATION BIO INC | 1.48% |
| NKTR NEKTAR THERAPEUTICS | 1.33% |
| BMY BRISTOL-MYERS SQUIBB COMPANY | 1.26% |
| ELAN ELANCO ANIMAL HEALTH INC | 1.23% |
| PCRX PACIRA BIOSCIENCES INC | 1.21% |
| VTRS VIATRIS INC | 1.19% |
| RPRX ROYALTY PHARMA PLC | 1.15% |
| COLL COLLEGIUM PHARMACEUTICAL INC | 1.09% |
| OGN ORGANON & COMPANY | 1.08% |
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
PHARMACEUTICALS ULTRASECTOR PROFUND (PHPSX) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A holding it cannot cover far enough is reported as unrated rather than counted as a pass.
| Holding | Weight | Verdict |
|---|---|---|
| N/Anot matched to a ticker | 8.20% | Not screened |
| N/Anot matched to a ticker | 6.31% | Not screened |
| N/Anot matched to a ticker | 5.05% | Not screened |
| N/Anot matched to a ticker | 5.05% | Not screened |
| N/Anot matched to a ticker | 3.95% | Not screened |
| CRINETICS PHARMACEUTICALS INCnot matched to a ticker | 2.60% | Not screened |
| MBX BIOSCIENCES INCnot matched to a ticker | 2.28% | Not screened |
| ATAIATAIBECKLEY INC | 2.03% | Non-compliant |
| DEFINIUM THERAPEUTICS INCnot matched to a ticker | 2.00% | Not screened |
| AMYLYX PHARMACEUTICALS INCnot matched to a ticker | 1.62% | Not screened |
Top 10 of 74 holdings, 39.1% of the fund by weight. Every holding is screened, not only these.
The positions keeping this fund short of 100% compliant by weight.
Verdict history for PHPSX. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
ℹ️ no compliance scan has run for 3 days - this is not a reading of today
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
This fund prices once a day, so its bars carry no intraday high or low — floor-trader pivots are not defined for it.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 40.70 | NEUTRAL |
| Stochastic %K (14) | 28.87 | NEUTRAL |
| CCI (20) | -48.57 | NEUTRAL |
| Williams %R (14) | -71.13 | NEUTRAL |
| MACD (12,26,9) | -0.09 | SELL |
| ROC (10) | -3.60 | SELL |
| Momentum (10) | -1.26 | SELL |
| EMA (10) | 33.60 | BUY |
| SMA (10) | 33.53 | BUY |
| EMA (20) | 34.61 | SELL |
| SMA (20) | 34.68 | SELL |
| EMA (30) | 35.31 | SELL |
| SMA (30) | 35.88 | SELL |
| EMA (50) | 35.80 | SELL |
| SMA (50) | 37.23 | SELL |
| EMA (100) | 34.96 | SELL |
| SMA (100) | 35.33 | SELL |
| EMA (200) | 32.15 | BUY |
| SMA (200) | 31.95 | BUY |
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
The questions worth asking about any verdict on this page, answered plainly.
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.